Last reviewed · How we verify
NCT05255042: TIMOLD
Tissue Models for Liver Disease
trial testing organ and tissue sample collection only in Liver Diseases in 24 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | University of Leicester |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 24 |
| Start date | 8 September 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- organ and tissue sample collection only
Conditions studied
- Liver Diseases — all drugs for Liver Diseases →
Sponsor
University of Leicester
Who can join
18 and older, any sex, with Liver Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The human immune response to bacterial and viral local and systemic infection are fairly well understood, but we lack details on the earliest phases. Better knowledge of these events would be important for the prevention and treatment of severe bacterial or viral disease. From models of infection, we have data showing that bacteria replicate in a specific type of cells in the liver from where the bacteria then seed to the blood to cause blood stream infection. In order to gain more relevant data for humans, we have developed a spleen and liver perfusion model using pig organs. This model confirms our previous work and most importantly will now allow us to study these events in human organs. Primary Objectives: The primary objective of the study is to identify therapies acting on the initial events during invasive bacterial and viral infection. Secondary Objectives: The secondary objective of this study is to provide novel in vitro and ex vivo models of human liver macrophages to study the impact of therapies for invasive infection. The Primary Endpoint of the study is to increase the resistance of liver macrophages to infection at least tenfold after treatment. The Primary Outcome Measure of the study is the reduction of bacterial or viral load at pre-determined time-points.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05255042
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Diseases
Currently open trials in the same condition.
- NCT07400289 — Development of a FibroScan Liver Examination Using a Single Probe · NA · recruiting
- NCT07150624 — The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine · Phase 4 · recruiting
- NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
- NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting
- NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
Other University of Leicester trials
Trials by the same sponsor.
- NCT07389785 — Age Related Chromatin Remodelling as a Therapeutic Target for Organ Protection in Cardiac Surgery · active not recruiting
- NCT07014579 — Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People · not yet recruiting
- NCT06955663 — Exercise Support and Rehabilitation for Patients After Spontaneous Coronary Artery Dissection · NA · recruiting
- NCT06629675 — Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD · NA · recruiting
- NCT06844656 — Understanding the Increased Risk of Atrial Fibrillation in Athletes: a Case-control Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05255042 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Leicester
- Last refreshed: 25 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05255042.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing